Diabetes
Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
Can Galician Olive Oil Help Control Blood Sugar?
A 24-week trial finds high-phenolic olive oil reduces insulin resistance in type 2 diabetes, but without changing lipids or blood pressure. PICO summary and commentary.
Does the Omnipod 5 Activity Feature Help Control Blood Sugar During Exercise?
A crossover trial finds the Omnipod 5 Activity feature reduces insulin and blunts exercise glucose drops in type 1 diabetes, though hypoglycemia rates were unchanged. PICO summary and commentary.
Is Nanocurcumin Safe and Effective for Diabetic Nerve Pain?
A double-blind RCT finds nanocurcumin does not improve pain or neuropathy outcomes in diabetic peripheral neuropathy. PICO summary and expert commentary.
Does Slower Semaglutide Titration Improve Tolerability and Adherence?
A randomized open-label pilot trial tested whether slower, flexible semaglutide titration reduces gastrointestinal dropout in type 2 diabetes versus the label regimen. PICO summary and expert commentary.
Can mHealth Improve Communication Between Patients and Providers?
A secondary analysis of the DIAMANTE trial finds an adaptive texting intervention did not improve patient-provider communication in diabetes and depression. PICO summary and commentary.
Empagliflozin Lowers Norepinephrine Turnover Despite Raising Hepatic Glucose Production
A mechanistic randomized trial found empagliflozin reduced total-body norepinephrine turnover at 1 day and 12 weeks even as hepatic glucose production rose, with the two changes inversely correlated. PICO summary and expert commentary.